Plaintiffs suing over the blood-thinner Xarelto are manipulating the pool of cases set for trial and crowding the docket with claims that should not have been filed, two drug companies have claimed as part of their effort to revamp how the next wave of Xarelto cases should be selected for trial in Philadelphia.

The plaintiffs shot back with a claim that defendants have made misleading statements to the court in hopes of steering the judge to adopt an unfair selection process.